• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙型肝炎病毒感染的器官供体在心胸移植中的应用:国际心脏和肺移植学会专家共识声明

Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement.

作者信息

Aslam Saima, Grossi Paolo, Schlendorf Kelly H, Holm Are M, Woolley Ann E, Blumberg Emily, Mehra Mandeep R

出版信息

J Heart Lung Transplant. 2020 May;39(5):418-432. doi: 10.1016/j.healun.2020.03.004. Epub 2020 Mar 19.

DOI:10.1016/j.healun.2020.03.004
PMID:32362393
Abstract

The advent of therapies for successful treatment of hepatitis C virus has allowed the heart and lung transplant community to re-explore the use of hepatitis C virus-positive donors for organ transplantation, with a benefit for many terminally ill patients. The consensus statements provided herein represent the current state of knowledge and expertise in this area, which we expect will continue to rapidly evolve over the next few years.

摘要

丙型肝炎病毒成功治疗方法的出现,使得心脏和肺移植领域能够重新探索使用丙型肝炎病毒阳性供体进行器官移植,这对许多绝症患者有益。本文提供的共识声明代表了该领域目前的知识和专业水平,我们预计在未来几年这一领域将继续迅速发展。

相似文献

1
Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement.丙型肝炎病毒感染的器官供体在心胸移植中的应用:国际心脏和肺移植学会专家共识声明
J Heart Lung Transplant. 2020 May;39(5):418-432. doi: 10.1016/j.healun.2020.03.004. Epub 2020 Mar 19.
2
New insights into the rational use of HCV+ organs worldwide.全球对 HCV+ 器官合理使用的新见解。
Clin Transplant. 2019 Dec;33(12):e13739. doi: 10.1111/ctr.13739. Epub 2019 Nov 8.
3
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.HCV 感染供体的心肺移植到未感染受者。
N Engl J Med. 2019 Apr 25;380(17):1606-1617. doi: 10.1056/NEJMoa1812406. Epub 2019 Apr 3.
4
Hepatitis C virus and nonliver solid organ transplantation.丙型肝炎病毒与非肝脏实体器官移植。
Transplantation. 2013 Mar 27;95(6):779-86. doi: 10.1097/TP.0b013e318273fec4.
5
HCV-infected solid organ donors, direct-acting antivirals and the current challenges.丙型肝炎病毒感染的实体器官供者、直接作用抗病毒药物和当前的挑战。
Expert Rev Clin Pharmacol. 2020 Jan;13(1):7-14. doi: 10.1080/17512433.2020.1697677. Epub 2019 Dec 22.
6
Hepatitis C virus genotyping of organ donor samples to aid in transplantation of HCV-positive organs.对器官供体样本进行丙型肝炎病毒基因分型,以助力丙型肝炎病毒阳性器官的移植。
Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13172. Epub 2017 Dec 21.
7
New updates in the world of hepatitis C virus infected organ transplantation.丙型肝炎病毒感染器官移植领域的新进展。
Curr Opin Organ Transplant. 2020 Aug;25(4):364-370. doi: 10.1097/MOT.0000000000000785.
8
Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience.接受丙型肝炎病毒感染供体心脏进行移植:多步骤同意、未实现的机会和斯坦福经验。
Clin Transplant. 2018 Jul;32(7):e13308. doi: 10.1111/ctr.13308. Epub 2018 Jun 21.
9
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明:2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.
10
Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?直接作用抗病毒药物与器官移植:我们还有什么不能做的吗?
J Infect Dis. 2020 Nov 27;222(Suppl 9):S794-S801. doi: 10.1093/infdis/jiaa420.

引用本文的文献

1
Expanding the Donor Pool.扩大供体库。
Methodist Debakey Cardiovasc J. 2025 May 15;21(3):33-39. doi: 10.14797/mdcvj.1577. eCollection 2025.
2
Heart transplantation with super-aged donors older than 65 years.使用65岁以上超高龄供体进行心脏移植。
JHLT Open. 2024 Mar 15;4:100083. doi: 10.1016/j.jhlto.2024.100083. eCollection 2024 May.
3
Revolutionizing Donor Heart Procurement: Innovations and Future Directions for Enhanced Transplantation Outcomes.革新供体心脏获取:改善移植结果的创新与未来方向
J Cardiovasc Dev Dis. 2024 Jul 27;11(8):235. doi: 10.3390/jcdd11080235.
4
Getting out of the box: the future of the UK donation after circulatory determination of death heart programme.突破常规:英国循环判定死亡后心脏捐赠项目的未来
EClinicalMedicine. 2023 Nov 19;66:102320. doi: 10.1016/j.eclinm.2023.102320. eCollection 2023 Dec.
5
Early Assessment of Cardiac Allograft Vasculopathy Risk Among Recipients of Hepatitis C Virus-infected Donors in the Current Era.在当前时代,评估丙型肝炎病毒感染供者受者心脏移植后血管病的风险。
J Card Fail. 2024 May;30(5):694-700. doi: 10.1016/j.cardfail.2023.09.015. Epub 2023 Oct 29.
6
To decline or not to decline: Consequences of decision-making regarding lung offers from donors with hepatitis C.是否拒绝:对丙型肝炎供体肺部捐献做出决策的后果。
J Thorac Cardiovasc Surg. 2024 Jun;167(6):1967-1976.e2. doi: 10.1016/j.jtcvs.2023.08.046. Epub 2023 Sep 9.
7
Heart transplantation: advances in expanding the donor pool and xenotransplantation.心脏移植:扩大供体库及异种移植方面的进展
Nat Rev Cardiol. 2024 Jan;21(1):25-36. doi: 10.1038/s41569-023-00902-1. Epub 2023 Jul 14.
8
The 2-year postoperative left heart function in marginal donor heart recipients assessing by speckle tracking echocardiography.斑点追踪超声心动图评估边缘供心受者术后 2 年左心功能。
Int J Cardiovasc Imaging. 2023 Aug;39(8):1449-1459. doi: 10.1007/s10554-023-02867-1. Epub 2023 May 15.
9
The Cost-effectiveness of Transplanting Hearts From Hepatitis C-infected Donors Into Uninfected Recipients.从丙型肝炎感染供体向未感染受者移植心脏的成本效益。
Transplantation. 2023 Apr 1;107(4):961-969. doi: 10.1097/TP.0000000000004378. Epub 2022 Oct 27.
10
A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir.一项关于使用短疗程格卡瑞韦/哌仑他韦预防丙型肝炎病毒从供体传播至器官移植受者的试点试验。
Open Forum Infect Dis. 2022 Oct 27;9(11):ofac550. doi: 10.1093/ofid/ofac550. eCollection 2022 Nov.